Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.17
$0.087.34%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 239.80M | 215.77M | 232.43M | 269.97M | 269.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 239.80M | 215.77M | 232.43M | 269.97M | 269.97M |
| Cost of Revenue | 87.53M | 80.26M | 85.88M | 97.15M | 97.15M |
| Gross Profit | 152.27M | 135.51M | 146.55M | 172.82M | 172.82M |
| SG&A Expenses | 100.80M | 88.53M | 104.04M | 116.13M | 116.13M |
| Depreciation & Amortization | -- | -- | -3.91M | -- | -- |
| Other Operating Expenses | -1.38M | -56.90K | -616.40K | -371.90K | -371.90K |
| Total Operating Expenses | 186.95M | 168.73M | 185.40M | 212.90M | 212.90M |
| Operating Income | 52.85M | 47.04M | 47.03M | 57.07M | 57.07M |
| Income Before Tax | 28.55M | 34.34M | 29.85M | 48.91M | 48.91M |
| Income Tax Expenses | 10.35M | 9.91M | 8.56M | 12.25M | 12.25M |
| Earnings from Continuing Operations | 18.20M | 24.42M | 21.29M | 36.66M | 36.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.20M | 24.42M | 21.29M | 36.66M | 36.66M |
| EBIT | 52.85M | 47.04M | 47.03M | 57.07M | 57.07M |
| EBITDA | 57.57M | 51.79M | 53.07M | 60.54M | 60.54M |
| EPS Basic | 0.02 | 0.03 | 0.02 | 0.04 | 0.04 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| EPS Diluted | 0.02 | 0.03 | 0.02 | 0.04 | 0.04 |
| Normalized Diluted EPS | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| Average Basic Shares Outstanding | 986.02M | 977.88M | 986.44M | 942.75M | 942.75M |
| Average Diluted Shares Outstanding | 986.02M | 977.88M | 986.44M | 942.75M | 942.75M |
| Dividend Per Share | -- | 0.01 | 0.03 | -- | -- |
| Payout Ratio | 0.00% | 39.18% | 42.86% | 32.96% | 32.96% |